Profile data is unavailable for this security.
About the company
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
- Revenue in USD (TTM)0.00
- Net income in USD-120.74m
- Incorporated2016
- Employees140.00
- LocationTenaya Therapeutics Inc171 Oyster Point Blvd., Suite 500SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 865-2066
- Fax+1 (302) 655-5049
- Websitehttps://www.tenayatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | 27.15m | -27.95m | 162.37m | 101.00 | -- | 13.88 | -- | 5.98 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Skye Bioscience Inc | 0.00 | -42.29m | 166.56m | 11.00 | -- | 2.12 | -- | -- | -3.91 | -3.91 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -94.50 | -232.67 | -129.40 | -- | -- | -- | -- | -- | -- | -323.10 | 0.0626 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Context Therapeutics Inc | 0.00 | -18.57m | 167.25m | 5.00 | -- | 1.65 | -- | -- | -1.06 | -1.06 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -28.46 | -- | -29.68 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -171.30m | 167.49m | 73.00 | -- | 0.5964 | -- | -- | -2.79 | -2.79 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.07 | -- | -55.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 6.19m | -24.19m | 171.84m | 75.00 | -- | 2.52 | -- | 27.78 | -0.1342 | -0.1342 | 0.0343 | 0.3617 | 0.0577 | -- | 18.25 | 82,480.00 | -22.57 | -19.53 | -26.03 | -22.59 | 90.83 | 89.13 | -391.25 | -370.88 | -- | -- | 0.0017 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.90m | 172.70m | 18.00 | -- | 3.23 | -- | -- | -0.5238 | -0.5238 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -33.49 | -45.38 | -34.98 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Tenaya Therapeutics Inc | 0.00 | -120.74m | 172.77m | 140.00 | -- | 1.29 | -- | -- | -1.54 | -1.54 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -62.89 | -- | -69.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 591.86k | -121.64m | 173.70m | 122.00 | -- | 1.80 | -- | 293.48 | -5.11 | -5.11 | 0.0248 | 3.73 | 0.0032 | -- | 0.6652 | 4,851.31 | -66.32 | -59.52 | -84.33 | -71.29 | -- | -- | -20,552.24 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Immunic Inc | 0.00 | -95.31m | 175.65m | 77.00 | -- | 2.76 | -- | -- | -1.51 | -1.51 | 0.00 | 0.7058 | 0.00 | -- | -- | 0.00 | -108.78 | -72.09 | -141.92 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Shattuck Labs Inc | 4.12m | -85.28m | 176.59m | 75.00 | -- | 1.60 | -- | 42.82 | -1.85 | -1.85 | 0.0883 | 2.32 | 0.029 | -- | -- | 54,986.67 | -60.08 | -29.14 | -66.66 | -32.42 | -- | -- | -2,067.99 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Galectin Therapeutics Inc | 0.00 | -48.03m | 176.87m | 14.00 | -- | -- | -- | -- | -0.7831 | -0.7831 | 0.00 | -1.32 | 0.00 | -- | -- | 0.00 | -185.54 | -92.08 | -382.33 | -121.97 | -- | -- | -- | -- | -- | -8.59 | 8.29 | -- | -- | -- | -15.26 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -25.91m | 183.61m | 10.00 | -- | 2.29 | -- | -- | -0.2064 | -0.2064 | 0.00 | 0.6374 | 0.00 | -- | -- | 0.00 | -26.68 | -29.97 | -28.00 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Jun 2024 | 7.62m | 9.66% |
| Casdin Capital LLCas of 30 Jun 2024 | 6.73m | 8.54% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 3.38m | 4.29% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.34m | 4.23% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.10m | 3.93% |
| Octagon Capital Advisors LPas of 30 Jun 2024 | 2.58m | 3.27% |
| Integral Health Asset Management LLCas of 30 Jun 2024 | 2.33m | 2.95% |
| Citadel Advisors LLCas of 30 Jun 2024 | 2.14m | 2.72% |
| Ghost Tree Capital LLCas of 30 Jun 2024 | 1.35m | 1.71% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 1.32m | 1.67% |
